http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018088682-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0e67818ab2d3b97121031ecfbb559e1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2017-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_565b83a3dccac8a1d4bc328d8cf1df40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33cd99cb79cd1d44ef57f7041a8ba6f2 |
| publicationDate | 2018-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018088682-A1 |
| titleOfInvention | Pharmaceutical composition for inhibiting cancer metastasis, containing tetraarsenic oxide |
| abstract | The present invention relates to a pharmaceutical composition for inhibiting cancer metastasis, containing tetraarsenic oxide (As 4 O 6 ). As 4 O 6 has been confirmed to inhibit cancer cell infiltration and migration mediated by an epidermal growth factor receptor (EGFR) and a human epidermal growth factor receptor-2 (HER-2) and to have an inhibitory effect superior to that of As 2 O 3 , and thus is expected to be usable as a therapeutic agent for preventing or inhibiting cancer metastasis. |
| priorityDate | 2016-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.